TY  - JOUR
A1  - Moench, Romana
A1  - Grimmig, Tanja
A1  - Kannen, Vinicius
A1  - Tripathi, Sudipta
A1  - Faber, Marc
A1  - Moll, Eva-Maria
A1  - Chandraker, Anil
A1  - Lissner, Reinhard
A1  - Germer, Christoph-Thomas
A1  - Waaga-Gasser, Ana Maria
A1  - Gasser, Martin
T1  - Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer
JF  - Oncotarget
N2  - Platelet-derived growth factor (PDGF) and signaling via its receptors plays a crucial role in tumor cell proliferation and thus may represent an attractive target besides VEGF/EGFR-based antibody therapies. In this study we analyzed the influence of PDGF in colorectal cancer. PDGF was expressed intensively in early and even more intensively in late stage primary CRCs. Like VEGF, PDGF enhanced human colon cancer proliferation, and increased oxidative glycolytic activity, and activated HIF1α and c-Myc in vitro. PDGF activated the PI3K/Akt/mTOR pathway while leaving MAPK signaling untouched. Further dissection showed that inhibition of Akt strongly impeded cancer cell growth while inhibition of PI3K did not. MAPK analysis suggested an inhibitory crosstalk between both pathways, thus explaining the different effects of the Akt and PI3K inhibitors on cancer cell proliferation. PDGF stimulates colon cancer cell proliferation, and prevents inhibitor induced apoptosis, resulting in tumor growth. Therefore inhibition of PDGF signaling seems to be a promising target in colorectal cancer therapy. However, due to the multifaceted nature of the intracellular PDGF signaling, careful intervention strategies are needed when looking into specific signaling pathways like PI3K/Akt/mTOR and MAPK.
KW  - PDGF
KW  - colorectal cancer
KW  - MAPK pathway
KW  - glucose metabolism
KW  - PI3K/Akt/mTOR
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-176910
VL  - 7
IS  - 42
ER  -